WADA Symposium Covers Broad Spectrum of Gene Doping, and Potential for Misuse of Cell Therapy in World of Sport
Posted on: 7 June 2013, source: WADA
Leading experts in gene therapy, scientists from the field of anti-doping, and sport ethicists joined WADA’s Gene Doping Panel at the Agency’s Fourth Gene and Cell Doping Symposium, held June 5-6 in Beijing to review recent achievements in the field and share the most promising approaches in doping detection under development. Organized with the support of the China Anti-Doping Agency (CHINADA) and Beijing Olympic City Development Association (BODA), the Symposium attracted more than 70 international participants. Sixteen invited speakers included international experts who either study the latest advances in the field of gene therapy and gene doping detection methods, or are involved in related WADA-funded research projects. The 2013 Symposium was the first to dedicate a formal session to cell therapy and doping.
Public consultation on advanced therapy medicinal products: A summary of the responses
Posted on: 30 May 2013, source: European Commission
The European Commission should prepare a report on the application of Regulation (EC) No 1394/2007 on advanced therapy medicinal products. With a view to prepare this report, the Commission services launched a public consultation on 20 December 2012. Stakeholders were invited to provide their views on the requirements to obtain a marketing authorisation for an ATMP (including for combined ATMPs), on the application of the so-called hospital exemption, on the incentives provided for in the ATMP Regulation, as well as on the scope thereof and its adaptation to technical progress. The number of contributions received was 63.
Scientists reveal inside story of European regulatory review and approval of Glybera
Posted on: 23 May 2013, source: News Medical
The scientists who led the team that developed Glybera, the first gene therapy drug approved for use in the Western world, provide a fascinating first-person account of their pioneering work in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. In addition, an in-depth Review revealing the inside story of the European regulatory review and approval of Glybera—chock full of twists and turns, politics, and intrigue— and critiquing the groundbreaking drug's path to the marketplace appears in Human Gene Therapy Clinical Development. Both articles are available free on the Human Gene Therapy website.
EMA Consultation: Draft guideline on the clinical investigation of medicinal products for the treatment of Duchenne and Becker muscular dystrophy
Posted on: 13 May 2013, source: EMA
The European Medicines Agency has recently published a draft guideline on the clinical investigation of medicinal products for the treatment of Duchenne and Becker muscular dystrophy. Recent advances in basic and clinical research have opened new perspectives for future therapeutic options in Duchenne and Becker muscular dystrophy (DBMD). As most of the cases of Duchenne muscular dystrophy (DMD) have an onset in early childhood, while the onset of Becker muscular dystrophy (BMD) covers a broader age spectrum, specific difficulties have been identified that pertain to diagnostic criteria, age- and stage related clinical relevance and different safety aspects.
Netherlands Gene Therapy Office launches website
Posted on: 12 May 2013, source: Gene Therapy Office
The aim of the governmental Gene Therapy Office is to streamline the licensing and permit granting procedures for clinical gene therapy studies in The Netherlands and to provide more insight into the procedures for investigators. The Gene Therapy Office is primarily a service for professionals conducting clinical gene therapy research involving human subjects. The official website is www.loketgentherapie.nl.
T-Cell Therapy for ALL Shows Benefit
Posted on: 28 March 2013, source: MedPageToday
Researchers reported encouraging but preliminary results of gene-based immune therapy in two children with relapsed and refractory acute lymphoblastic leukemia (ALL). Both children achieved a remission after they were given T cells modified to attack B cells bearing the surface protein CD19, according to Stephan A. Grupp, MD, PhD, of the Children's Hospital of Philadelphia, and colleagues.
Lentigen wins US Orphan Drug Designation for glioblastoma
Posted on: 28 February 2013, source: Lentigen
Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery products, announced today that that the U.S. Food and Drug Administration (FDA) has granted orphan drug status to P140K methylguanine methyltransferase (MGMT) transduced human CD34 cells (product name: LG631-CD34) for bone marrow protection in the treatment of glioblastoma multiforme. Orphan drug designation qualifies Lentigen for seven years of market exclusivity following marketing approval by the FDA and provides other development-related incentives.
Translating the Genomics Revolution: The Need for an International Gene Therapy Consortium for Monogenic Diseases
Posted on: 5 February 2013, source: Molecular Therapy
In the latest issue of the journal Molecular Therapy, Professor Jacques P. Tremblay (president of the Association of Gene Therapy of Quebec and researcher in the Research center of the Centre Hospitalier Universitaire (CHU) of Quebec) launches a call - with 50 other world experts in gene therapy - for the creation of an International Gene Therapy Consortium for Monogenic Diseases. The bases of this consortium will be established during a workshop, which will be held during the congress of the American Society of Gene and Cell Therapy (ASGCT) in Salt Lake City in May 2013.
Another Bump in the Road to Gene Therapy?
Posted on: 1 February 2013, source: PlosBlogs
By Ricki Lewis - I am astonished, once again, by the complexity and unpredictability of science. Last week, a paper in the Proceedings of the National Academy of Science (PNAS) reported that gene therapy to treat a form of blindness called Leber congenital amaurosis type 2 (LCA2) doesn’t stop degeneration of the rods and cones – the photoreceptor cells that provide vision. Gene therapy sends genetic instructions for a protein called RPE65 into a layer of cells that supports the rods and cones – the retinal pigment epithelium, or RPE. The protein is essential for the eye to use vitamin A. And the gene therapy works, so far.
New Gene Therapy Extends Lives Of Children With Rare Brain Disorder
Posted on: 24 January 2013, source: Sinq
Chalk up another victory for gene therapy. A recent clinical trial has shown that gene therapy can be used to extend the lives of children with a rare brain disorder that typically proves fatal in the first few years of life. The oldest child to benefit from this reversal of fortune has reached an amazing 18 years of age.
Positive gene therapy results in large mammals of Duchenne muscular dystrophy
Posted on: 17 January 2013, source: NewsMedical
Usually, results from a new study help scientists inch their way toward an answer whether they are battling a health problem or are on the verge of a technological breakthrough. Once in a while, those results give them a giant leap forward. In a preliminary study in a canine model of Duchenne muscular dystrophy (DMD), University of Missouri scientists showed exactly such a leap using gene therapy to treat muscular dystrophy. The results of the study will be published in the journal Molecular Therapy on Jan. 15, 2013.
MIT researchers crack cheap, precise gene therapy
Posted on: 11 January 2013, source: ExtremeTech
Disease is on the run! An incredible advance in the realm of gene therapy has been made by top researchers in the US and Sweden. A single enzyme from a bacteria’s immune system can effectively be used to locate specific sections of DNA in a living cell. From there, entire genes can be neutralized or replaced with superior sections of DNA. Clearly, we are on the brink of gene therapy becoming a common and highly effective treatment for terrible diseases like AIDS and cancer.
Shape matters in DNA nanoparticle therapy
Posted on: 14 December 2012, source: National Cancer Institute
Researchers from The Johns Hopkins University and Northwestern University have discovered how to control the shape of nanoparticles that move DNA through the body and have shown that the shapes of these carriers may make a big difference in how well they work in treating cancer and other diseases. The results of this study, which were published in the journal Advanced Materials ("Plasmid-Templated Shape Control of Condensed DNA–Block Copolymer Nanoparticles"), are also noteworthy because this gene therapy technique does not use a virus to carry DNA into cells. “These nanoparticles could become a safer and more effective delivery vehicle for gene therapy targeting cancer and other illnesses than can be treated with gene medicine,” said Hai-Quan Mao, of Johns Hopkins, who, together with Erik Luijten of Northwestern, led this research.
The CliniBook: clinical gene transfer state-of-the-art
Posted on: 23 November 2012, source: CliniGene
This book provides a reference for state-of-the-art gene transfer technology as of 2012 and the different aspects of its clinical translation with a focus on European-based initiatives. As examples of successful outcomes, recent clinical trials are presented together with ethical, safety and legal issues, which are discussed. This book is ideal for researchers, clinical investigarors, post-graduate fellows, undergraduate scholars, regulators, patients' advocacy groups and policy-makers, looking for state-of-the-art information as well as emerging prospects - including gene targeting and homologous recombination - for gene transfer intended for clinical translation. List of authors and table of contents.
Gene Therapy Net members can order now for a reduced price of 80 € (public price: 95 €).
uniQure's Glybera® First Gene Therapy Approved by European Commission
Posted on: 2 November 2012, source: uniQure
uniQure announced today it has received approval from the European Commission for the gene therapy Glybera® (alipogene tiparvovec), a treatment for patients with lipoprotein lipase deficiency (LPLD, also called familial hyperchylomicronemia) suffering from recurring acute pancreatitis. Patients with LPLD, a very rare, inherited disease, are unable to metabolize the fat particles carried in their blood, which leads to inflammation of the pancreas (pancreatitis), an extremely serious, painful, and potentially lethal condition. The approval makes Glybera the first gene therapy approved by regulatory authorities in the Western world.
DNA folded into shapes offers alternative gene delivery vehicle
Posted on: 18 October 2012, source: Nanowerk News
Researchers from Johns Hopkins and Northwestern universities have discovered how to control the shape of nanoparticles that move DNA through the body and have shown that the shapes of these carriers may make a big difference in how well they work in treating cancer and other diseases. This study, published in the Oct. 12 online edition of Advanced Materials is also noteworthy because this gene therapy technique does not use a virus to carry DNA into cells. Some gene therapy efforts that rely on viruses have posed health risks.
EMA Streamlines Working Parties
Posted on: 25 September 2012, source: PharmTech
The European Medicines Agency (EMA) has abolished its Cell-based Product Working Party (CPWP) and Gene Therapy Working Party (GTWP), with the aim of improving efficiencies and optimizing the use of available expertise. Instead, EMA’s Committee for Advanced Therapies (CAT) will be assuming the lead role in all aspects concerning the development of advanced-therapy medicines in Europe, including developing guidelines, organizing workshops and establishing ad-hoc draft groups as and when required to develop specific guidance documents. Guidance documents already being developed by CPWP or GTWP will be taken over by the new drafting groups
Researchers Improve Gene Therapy Technique for Children with Immune Disorder
Posted on: 12 September 2012, source: Healthcare Globa
Researchers enhance gene therapy approach for children with adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID) using chemotherapy as conditioning regimen. For the first time, investigators test two different viral vectors to transport normal genes into the young patients' bone marrow stem cells and two different treatment plans in preparation for receiving gene therapy and compare outcomes.
Scientists restore sense of smell in mice through gene therapy
Posted on: 3 September 2012, source: News-Medical
Scientists have restored the sense of smell in mice through gene therapy for the first time -- a hopeful sign for people who can't smell anything from birth or lose it due to disease. The achievement in curing congenital anosmia -- the medical term for lifelong inability to detect odors -- may also aid research on other conditions that also stem from problems with the cilia. Those tiny hair-shaped structures on the surfaces of cells throughout the body are involved in many diseases, from the kidneys to the eyes. The new findings, published online in Nature Medicine, come from a team at the University of Michigan Medical School and their colleagues at several other institutions
The cheat gene: Could the next step in sporting fraud come from manipulating DNA?
Posted on: 22 August 2012, source: The Independent
The London Olympics may turn out to be one of the cleanest in history in terms of banned substances – but behind the scenes, scientists fear the next big challenge to fair play in sport: gene doping. Over the past decade, scientific advances in the understanding of how genes control muscle activity have alarmed experts within the World Anti-Doping Agency (Wada) who believe that using genes, rather than drugs, will be the next way illicitly to boost athletic performance without fear of detection.
European Agency Recommends Gene Therapy Approval
Posted on: 22 July 2012, source: TodayOnline
European regulators have recommended approval of the Western world's first gene therapy drug - after rejecting it on three previous occasions - in a significant advance for the novel medical technology. More than 20 years since the first experiments with the ground-breaking method for fixing faulty genes, scientists and drug companies are still struggling to apply gene therapy in practice. Friday's decision by the European Medicines Agency (EMA) is a win for the drug's maker, the small Dutch biotech company uniQure, and a potential lifeline for patients with the ultra rare genetic disorder lipoprotein lipase deficiency (LPLD).
Nanoparticles Deliver Gene Therapy Directly to Skin Cells
Posted on: 5 July 2012, source: GEN
Scientists have developed an siRNA-carrying gold nanoparticle that they claim can be mixed with a commercial moisturizing cream to enable the topical delivery of gene-targeting therapeutics directly into deep skin layers. The Northwestern University team says the platform could lead to the development of topical forms of gene therapy for diseases such as skin cancer, inflammation, and genetic skin disorders.
Bluebird wins orphan drug designation for ALD treatment
Posted on: 20 June 2012, source: Boston Herald
Cambridge-based genetic disorder drug maker bluebird bio said today it has received an orphan drug designation from both the U.S. Food and Drug Administration and the European Medicines Agency for its investigational gene therapy designed to treat adrenoleukodystrophy. Known as ALD, adrenoleukodystrophy is a rare, inherited disorder that leads to progressive brain damage, failure of the adrenal glands and ultimately death. The company said it plans to initiate a Phase 2/3 clinical study in childhood cerebral ALD in both the U.S. and Europe next year.
Gene Therapy Society Looking to NIH to Revisit Role of the Recombinant DNA Advisory Committee
Posted on: 7 June 2012, source: GEN
The principal U.S. professional society representing gene therapists is awaiting word from NIH about whether or not there will be re-examination of the role of its Recombinant DNA Advisory Committee (RAC). They aim to limit its longstanding role in clinical trials while continuing its service as a forum for discussing and educating professionals on policy issues. The American Society of Gene & Cell Therapy (ASGCT) touched off the debate earlier this year, when its president and her predecessor conveyed the society’s view that RAC should focus on broader issues rather than review the clinical protocols of individual researchers. They sent a letter to Amy Patterson, M.D., director of NIH’s Office of Biotechnology Activities (OBA), and issued a statement seven days later at a RAC meeting.
Targeting DNA: After 20 years of high-profile failure, gene therapy is finally well on its way to clinical approval
Posted on: 6 June 2012, source: The Scientist
The concept is simple: if a mutated gene is causing a problem, replace or supplement it with a new, accurate copy. In theory, such a strategy could not just treat, but cure countless human genetic diseases. In practice, however, developing safe and effective gene therapies has not been easy. Even when identifying a disorder’s genetic basis is fairly straightforward, finding the appropriate delivery vector to target the diseased tissues in the body, while avoiding unintended consequences, has challenged would-be gene therapists for more than 20 years. But more and more researchers are convinced that the technique is on the brink of becoming a common medical practice.
RetroSense Therapeutics Completes pre-IND Meeting for RST-001
Posted on: 31 May 2012, source: PipelineReview
RetroSense Therapeutics, a gene therapy company dedicated to vision restoration, announced completion of a pre-IND meeting with the Center for Biological Evaluation and Research (CBER) division of the FDA that took place on May 22nd 2012 regarding RetroSense’s lead biologic, RST-001 for vision restoration in retinal degenerative conditions. The purpose of the meeting was to obtain CBER’s guidance for the clinical path to a Biologics License Application (BLA) for RST-001 in the US, and clarity on the steps required for Investigational New Drug (IND) submission. The discussions included manufacturing criteria, the scope and design of the preclinical studies, and the scope and design of Phase I and IIa clinical trials.
Gene Therapy in Ophthalmology Clinical Trial Details: An Attempt to Track the Number of Patients Treated to Date
Posted on: 20 May 2012, source: Irv Arons
In attempting to determine how many patients had been treated with gene therapy for eye disorders, Irv Arons quickly found that no one was keeping track – at least no one that he could find. So, Irv Arons decided to try and get this data. He has now found reliable data for more than two-thirds of the 15 clinical trials underway and presents this information in his new table.
Gene Therapy Safe in Decade-Long HIV Study That May Widen Use
Posted on: 3 May 2012, source: BloombergNews
HIV patients given gene therapy more than a decade ago are healthy and the altered DNA they received remains stable in their bodies, according to a study that scientists say proves the treatment may safely be tested as a way to attack other illnesses. All except two of 43 people treated with genetically- altered versions of their own infection-fighting T cells were healthy as many as 11 years later, according to the research reported today in the journal Science Translational Medicine.
Top Cancer Scientists Converge to Celebrate ACGT's 10th Anniversary and New Frontiers in Treating Cancer
Posted on: 19 April 2012, source: ACGT
More than 30 of the nation's top cancer research scientists are gathering in Greenwich, Conn., this week to compare notes, collaborate, and celebrate ACGT's 10 years of innovative cancer research funding. ACGT was the funding arm of the breakthrough Leukemia clinical trial study at the University of Pennsylvania last summer that obliterated the cancer in patients.
Brain gene therapy is beating my Parkinson's
Posted on: 14 April 2012, source: WRAL
Doctors in Britain say a radical new treatment for Parkinson's could improve the lives of millions who suffer from the disease. Sheila Roy says she can finally enjoy life at her countryside home in Cambridge, England. She has lived with Parkinson's disease for 17 years, but a team of Oxford scientists developed a treatment that changed her life. “I can see a glimmer of a person I use to be now, which is really exciting,” she said. Roy was one of only 15 people in the world to take part in a gene therapy experiment that was previously tested on lab animals. Scientists create and inject a virus into the brain. It jumpstarts the production of dopamine, a chemical that fights Parkinson's. Without dopamine, patients suffer tremors and uncontrolled movements.
- Potential gene therapy for patients with rare disease
- Study shows developing a gene therapy for cancer will be harder than scientists thought
- CHMP asks AMT to provide additional information on Glybera
- ACGT 2012 Investigator's Award in Clinical Translation of Gene Therapy for Pancreatic Cancer,
- NVGCT launches new website
- Amsterdam Molecular Therapeutics Announces European Commission Delays Decision on Glybera® Marketing Authorisation And Requests Further Information From the CHMP
- HSCI Receives Approval To Market Neovasculgen – The First Russian Gene Therapy Drug For Treatment Of Peripheral Arterial Disease
- Gene therapy proves effective for hemophilia B
- Gene Therapy Video on the CliniGene Website
- AMT Suspends Glybera and Plans 50% Job Cuts in Restructuring Moves
- Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
- Gene therapy and stem cells unite
- Gene Therapists Celebrate a Decade of Progress
- Sangamo gene therapy shows promise in reducing HIV
- Bubble Boys Treated With Gene Therapy Still Healthy After 9 Years
- Genetically modified cells destroy leukaemia tumours
- Evolution: A View from the 20th Century
- Survey on Risk Assessment in Clinical Trials
- Amsterdam Molecular Therapeutics Receives Opinion on Glybera Marketing Authorisation Application
- New approach to cancer vaccines proves successful in early studies
- A new start for gene therapy for “bubble boy” disease: First U.S.-treated patient doing well
- Monkey Vaccine Has Promise For Eventual Human HIV Vaccine
- Gene Therapy Will be a Vital Part of Future Health Care
- Moving gene therapy into high gear
- First Clinical Trial of Gene Therapy for Pain Shows Substantial Pain Relief for Patients
- EU Clinical Trials Register goes live
- Gene therapy a reality for Parkinson's
- NVGT Embraces Cell Therapy with Name Change
- Zinc finger gene therapy produces HIV-resistant CD4 T-cells
- New Anti-HIV Gene Therapy Makes T-Cells Resistant to HIV Infection
- Gene therapy to fix memory loss in Alzheimer's patients study
- The Use of Gene Therapy in Treating Retinitis Pigmentosa and Dry Age-related Macular Degeneration (AMD)
- NIH RAC and CliniGene Co-host a Scientific Symposium on 'Retroviral and Lentiviral Vectors for Long-Term Gene Correction: Clinical Challenges in Vector and Trial Design'
- First patient being treated by Stem cell therapy
- Leading gene therapy researcher retracts more papers
- Gene Therapy Stops Blood Disorder in Patient, Ending Need for Transfusions
- Gene Doping Detectable With a Simple Blood Test
- Public Workshop on Cell and Gene Therapy Clinical Trials in Pediatric Populations
- New Hope Against Melanoma
- Gene Therapy to Treat Epilepsy a Step Closer
- CliniGene Competitive Call for Additional Project Partners
- Study Shows Hope for Gene Therapy
- A Step Closer to Gene Therapy for HIV
- Oncolytic vaccine therapy shows promise in melanoma, SCC studies
- First-in-man gene therapy for advanced heart failure promising in small study
- Gene Therapy Reverses Muscle Weakness in MD
- Gene Therapy Plus Chemotherapy Ups Odds for Success in Treating 'Bubble Boy' Disease
- ‘Dead as Doornail’ Gene Therapy Revival Spurs Genzyme
- New Gene Therapy Breakthrough in Humans is Result of Research Pioneered at OHSU's Primate Center
- UF-led effort creates virus reference standard that can improve patient safety in clinical trials
- Nanotech robots deliver gene therapy through blood
- Scientists Still Hopeful About Gene Therapy's Promise
- Gene Therapy a Step Closer to Restoring Eyesight to Some Blind Patients
- Adeno-Associated Virus Type 2 Reference Standard Material is Now Available
- Amsterdam Molecular Therapeutics: EMA starts formal review of Glybera dossier
- The EMA has published a Concept paper on the revision of the note for guidance on the quality, pre-clinical and clinical aspects of gene transfer medicinal products
- Molecular Security System That Protects Cells from Potentially Harmful DNA Discovered
- Oxford BioMedica Receives Orphan Designation for Gene Therapy Treatment for Stargardt Disease
- Gene Therapy Halts Brain Disease in Two Boys
- Gene Therapy Repairs Injured Human Donor Lungs For The First Time
- One Shot Of Gene Therapy, And Children With Congenital Blindness Can Now See
- AMT Receives EMEA Orphan Drug Designation for Duchenne Muscular Dystrophy
- Scientists Use Gene Therapy To Cure Colorblind Monkeys
- The Second Coming of Gene Therapy
- Scientists Construct 'Off Switch' For Parkinson Therapy
- Study Clears Gene Therapy in Death of Arthritis Patient
- Clonal Population of Cells Detected in a Clinical Human Gene Transfer Trial Using Lentiviral Vector
- ASGT Embraces Cell Therapy with Name Change
- Moving Gene Therapy Forward With Mobile DNA
- Analysis: Gene therapy has immense potential
- Gene Therapy Gets Closer to a 'Cure'
- Ark Therapeutics Files Cerepro® Application for European Marketing Authorisation
- Proposed ASGT name change to the American Society of Gene and Cell Therapy (ASGCT)
- Gene Therapy For Blindness Improves Vision, Safety Study Indicates
- Introgen Submits ADVEXIN® Regulatory Applications in the U.S. and Europe
- Gene Therapy Improves Vision In Nearly Blind Patients
- Boy develops leukemia after gene therapy in UK
- FDA lifts ban on trial after investigating death
- FDA Statement on Gene Therapy Clinical Trial
- First Oncolytic Viral Therapy Approved for Head and Neck Cancer
- Third complication case in X-SCID gene therapy clinical trial
- Cancer gene therapy is first to be approved in China
- New cancer case halts US gene therapy trials
- 'Miracle' gene therapy trial halted